Feature | March 12, 2013

Mayo Study Questions if Imaging Agents Cause Acute Kidney Injury

Contrast Agents Mayo Clinic Clinical Study Kidney Injury

March 12, 2013 — Many physicians have long believed that the use of intravenous contrast agents for computed tomography (CT) scans can cause acute kidney injury. New Mayo Clinic research questions the strength of the causal link between the two. The findings from two tandem studies are published online in the journal Radiology.

The first study examined all previous research that compared patients who did or did not receive contrast agents, while the second paper represented a new retrospective study of over 100,000 CT scans performed at Mayo Clinic from 2000 to 2010, the largest published study to date examining the effect of contrast-enhanced imaging on renal function. In the retrospective study, researchers performed statistical analyses to study causality and mimic a randomized controlled trial to better match patients who received contrast agents to those patients who did not. These techniques had not been performed in any prior studies of renal function following contrast administration.

“These studies have significant clinical ramifications with regard to who is eligible to receive contrast media during CT exams,” says lead co-author Bob McDonald, M.D., Ph.D., a radiologist at Mayo Clinic. “Despite limited clinical evidence, contrast is commonly withheld during CT exams of individuals with even modest renal impairment due to concern for kidney injury, often at the expense of diagnostic accuracy of the exam. Our goal for these studies was to provide better evidence regarding the true incidence of renal injury following intravenous contrast administration and better define the ‘at-risk’ patient population.”

In both studies, Mayo Clinic researchers found that patients who received intravenous contrast agents and those who didn’t had a similar risk of developing acute kidney injury.

“Our findings suggest that, if contrast-induced nephropathy exists at all, it is likely rare and cannot be easily identified from unrelated causes of renal injury,” says lead co-author Jennifer McDonald, Ph.D., a radiology associate at Mayo Clinic. “Hopefully our findings can promote additional research to help redefine the safety window of contrast media and, in turn, improve patient care through more frequent use of appropriate clinical imaging.”

For more information: www.mayoclinic.org/about, www.mayoclinic.org/news

Related Content

Toshiba, Infinix 4-D CT, first U.S. install, Arkansas cancer center
News | CT Angiography (CTA)| May 26, 2016
Cancer patients at the Carti Cancer Center, Conway, Ark., now have access to the latest innovation in diagnostic...
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
Osprey Avert
News | Cath Lab| May 13, 2016
May 13, 2016 — In the largest study of its kind, a new device has been found to significantly reduce the volume of ra
Radiation dose management, radiation dose monitoring, X-ray dose

Analytics from Sectra’s radiation dose monitoring software showing procedures where dose levels were higher than normal for various X-ray modalities. 

Feature | Radiation Dose Management| May 12, 2016 | Lori Webb, R.T. (R) and Tom Watson, RCVT
Healthcare organizations, clinicians and medical equipment manufacturers have long focused on the management and redu
Hitachi Medical, Scenaria CT scanner, All-Inclusive Support program
Technology | Computed Tomography (CT)| May 02, 2016
May 2, 2016 — Hitachi Medical Systems America Inc.
MR angiography, MRA, Bayer, Gadavist, gadobutrol injection, FDA approval, supra-aortic arteries
Technology | Contrast Media| April 29, 2016
Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use...
coronary CT angiography, CCTA, SCOT-HEART trial substudy, SCCT
News | Computed Tomography (CT)| April 26, 2016
The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA)...
Toshiba, Aquilion Lightning CT, 50 kW generator, FDA clearance
News | Computed Tomography (CT)| April 20, 2016
April 19, 2016 — Toshiba America Medical Systems Inc.’s Aquilion Lightning...
FFR-CT, heartflow
Feature | CT Angiography (CTA)| April 15, 2016 | Jeff Zagoudis
Fractional flow reserve-computed tomography (FFR-CT) is still in the early stages of clinical implementation in the U
Overlay Init